Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Takeda Global Research & Development Center, Inc. |
---|---|
Information provided by: | Takeda Global Research & Development Center, Inc. |
ClinicalTrials.gov Identifier: | NCT00174941 |
A Phase 2, study to evaluate the long-term safety of febuxostat at doses (40, 80, and 120 mg QD) expected to maintain serum urate levels within clinically acceptable levels in subjects with gout.
Condition | Intervention | Phase |
---|---|---|
Gout |
Drug: Febuxostat 40 mg Drug: Febuxostat 80 mg Drug: Febuxostat 120 mg |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout |
Enrollment: | 116 |
Study Start Date: | March 2001 |
Study Completion Date: | February 2007 |
Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Febuxostat 40 mg
|
Drug: Febuxostat 40 mg
Daily orally for 5 years
|
2: Experimental
Febuxostat 80 mg
|
Drug: Febuxostat 80 mg
Daily orally for 5 years
|
3: Experimental
Febuxostat 120 mg
|
Drug: Febuxostat 120 mg
Daily orally for 5 years
|
A Phase 2, open label study to evaluate the long-term safety of febuxostat at doses (40, 80, and 120 mg QD) expected to maintain serum urate levels within clinically acceptable levels in subjects with gout. Subjects will have successfully completed study TMX-00-004
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science ) |
Study ID Numbers: | TMX-01-005 |
Study First Received: | September 12, 2005 |
Last Updated: | November 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00174941 |
Health Authority: | United States: Food and Drug Administration |
Uric acid gout xanthine oxidase febuxostat tophi |
Metabolism, Inborn Errors Uric Acid Metabolic Diseases Genetic Diseases, Inborn Musculoskeletal Diseases Joint Diseases |
Arthritis Febuxostat Rheumatic Diseases Metabolic disorder Purine-Pyrimidine Metabolism, Inborn Errors Gout |
Therapeutic Uses Antirheumatic Agents Gout Suppressants Pharmacologic Actions |